Cargando…

The BRD4 inhibitor JQ1 suppresses tumor growth by reducing c-Myc expression in endometrial cancer

BACKGROUND: Endometrial cancer (EC) is the most common gynecological malignancy in developed countries. Efficacy of the bromodomain 4 (BRD4) inhibitor JQ1 has been reported for the treatment of various human cancers, but its potential impact on EC remains unclear. We therefore aimed to elucidate the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pang, Yingxin, Bai, Gaigai, Zhao, Jing, Wei, Xuan, Li, Rui, Li, Jie, Hu, Shunxue, Peng, Lu, Liu, Peishu, Mao, Hongluan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9331486/ https://www.ncbi.nlm.nih.gov/pubmed/35902869 http://dx.doi.org/10.1186/s12967-022-03545-x

Ejemplares similares

Akt/mTOR-Mediated Autophagy Confers Resistance To BET Inhibitor JQ1 In Ovarian Cancer
por: Luan, Wenqing, et al.
Publicado: (2019)

Identification of Three Potential Prognostic Genes in Platinum-Resistant Ovarian Cancer via Integrated Bioinformatics Analysis
por: Zhang, Xue, et al.
Publicado: (2021)

Successful pregnancy following conservative management of low-grade endometrial stromal sarcoma: A case report
por: DONG, RUIYING, et al.
Publicado: (2014)

GABPA Expression in Endometrial Carcinoma: A Prognostic Marker
por: Ma, Xiaoxue, et al.
Publicado: (2021)

Overexpression of Nucleolin is a Potential Prognostic Marker in Endometrial Carcinoma
por: Lin, Qianhan, et al.
Publicado: (2021)

Low Density Lipoprotein Receptor (LDLR) and 3-Hydroxy-3-Methylglutaryl Coenzyme a Reductase (HMGCR) Expression are Associated with Platinum-Resistance and Prognosis in Ovarian Carcinoma Patients
por: Huang, Xueyao, et al.
Publicado: (2021)

Ferritinophagy is required for the induction of ferroptosis by the bromodomain protein BRD4 inhibitor (+)-JQ1 in cancer cells
por: Sui, Shiyao, et al.
Publicado: (2019)

Development of Nomogram Models Based on Peripheral Blood Score and Clinicopathological Parameters to Predict Preoperative Advanced Stage and Prognosis for Epithelial Ovarian Cancer Patients
por: Bai, Gaigai, et al.
Publicado: (2023)

The BET/BRD inhibitor JQ1 improves brain plasticity in WT and APP mice
por: Benito, E, et al.
Publicado: (2017)

Novel Nanocomplexes Targeting STAT3 Demonstrate Promising Anti-Ovarian Cancer Effects in vivo
por: Zhang, Xiaolei, et al.
Publicado: (2020)

The BET bromodomain inhibitor, JQ1, facilitates c-FLIP degradation and enhances TRAIL-induced apoptosis independent of BRD4 and c-Myc inhibition
por: Yao, Weilong, et al.
Publicado: (2015)

BRD4 inhibitor JQ1 inhibits and reverses mechanical injury-induced corneal scarring
por: Qu, Mingli, et al.
Publicado: (2018)

JQ1 as a BRD4 Inhibitor Blocks Inflammatory Pyroptosis-Related Acute Colon Injury Induced by LPS
por: Chen, Ling, et al.
Publicado: (2021)

Transcriptome analysis of dominant-negative Brd4 mutants identifies Brd4-specific target genes of small molecule inhibitor JQ1
por: Decker, Tim-Michael, et al.
Publicado: (2017)

MiR-519d represses ovarian cancer cell proliferation and enhances cisplatin-mediated cytotoxicity in vitro by targeting XIAP
por: Pang, Yingxin, et al.
Publicado: (2014)

The BRD4 inhibitor JQ1 augments the antitumor efficacy of abemaciclib in preclinical models of gastric carcinoma
por: Feng, Mei, et al.
Publicado: (2023)

VDAC1 is regulated by BRD4 and contributes to JQ1 resistance in breast cancer
por: Yang, Guochao, et al.
Publicado: (2019)

The BET bromodomain inhibitor JQ1 activates HIV latency through antagonizing Brd4 inhibition of Tat-transactivation
por: Li, Zichong, et al.
Publicado: (2013)

Targeting ACLY Attenuates Tumor Growth and Acquired Cisplatin Resistance in Ovarian Cancer by Inhibiting the PI3K–AKT Pathway and Activating the AMPK–ROS Pathway
por: Wei, Xuan, et al.
Publicado: (2021)

Corrigendum: Targeting ACLY Attenuates Tumor Growth and Acquired Cisplatin Resistance in Ovarian Cancer by Inhibiting the PI3K–AKT Pathway and Activating the AMPK–ROS Pathway
por: Wei, Xuan, et al.
Publicado: (2021)

BET protein Brd4 activates transcription in neurons and BET inhibitor Jq1 blocks memory in mice
por: Korb, Erica, et al.
Publicado: (2015)

BET bromodomain inhibitor JQ1 preferentially suppresses EBV-positive nasopharyngeal carcinoma cells partially through repressing c-Myc
por: Li, Ning, et al.
Publicado: (2018)

Small Molecule BRD4 Inhibitors Apabetalone and JQ1 Rescues Endothelial Cells Dysfunction, Protects Monolayer Integrity and Reduces Midkine Expression
por: Shahid, Sidra, et al.
Publicado: (2022)

Bromodomain protein BRD4 inhibitor JQ1 regulates potential prognostic molecules in advanced renal cell carcinoma
por: Sakaguchi, Takashi, et al.
Publicado: (2018)

Bromodomains and Extra-Terminal (BET) Inhibitor JQ1 Suppresses Proliferation of Acute Lymphocytic Leukemia by Inhibiting c-Myc-Mediated Glycolysis
por: Zhang, Meng-Yi, et al.
Publicado: (2020)

Regulation of MYC Expression and Differential JQ1 Sensitivity in Cancer Cells
por: Fowler, Trent, et al.
Publicado: (2014)

Inhibition of Brd4 by JQ1 Promotes Functional Recovery From Spinal Cord Injury by Activating Autophagy
por: Li, Yao, et al.
Publicado: (2020)

Synergistic inhibition of pancreatic cancer with anti-PD-L1 and c-Myc inhibitor JQ1
por: Pan, Yu, et al.
Publicado: (2019)

Affinity Map of Bromodomain Protein 4 (BRD4) Interactions with the Histone H4 Tail and the Small Molecule Inhibitor JQ1
por: Jung, Marie, et al.
Publicado: (2014)

BRD4 associates with p53 in DNMT3A-mutated leukemia cells and is implicated in apoptosis by the bromodomain inhibitor JQ1
por: Stewart, Helen Jayne Susan, et al.
Publicado: (2013)

Correction: Regulation of MYC Expression and Differential JQ1 Sensitivity in Cancer Cells
por: Fowler, Trent, et al.
Publicado: (2015)

JQ1 suppresses tumor growth via PTEN/PI3K/AKT pathway in endometrial cancer
por: Qiu, Haifeng, et al.
Publicado: (2016)

Emodin suppresses proliferation, migration and invasion in ovarian cancer cells by down regulating ILK in vitro and in vivo
por: Lu, Jingjing, et al.
Publicado: (2017)

BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells
por: Coudé, Marie-Magdelaine, et al.
Publicado: (2015)

Suppression of BRD4 inhibits human hepatocellular carcinoma by repressing MYC and enhancing BIM expression
por: Li, Gong-Quan, et al.
Publicado: (2015)

ROR2 induces cell apoptosis via activating IRE1α/JNK/CHOP pathway in high-grade serous ovarian carcinoma in vitro and in vivo
por: Li, Rui, et al.
Publicado: (2019)

Potent BRD4 inhibitor suppresses cancer cell-macrophage interaction
por: Yin, Mingzhu, et al.
Publicado: (2020)

JQ1 affects BRD2-dependent and independent transcription regulation without disrupting H4-hyperacetylated chromatin states
por: Handoko, Lusy, et al.
Publicado: (2018)

GLI2-dependent c-MYC upregulation mediates resistance of pancreatic cancer cells to the BET bromodomain inhibitor JQ1
por: Kumar, Krishan, et al.
Publicado: (2015)

BET bromodomain inhibitor (JQ1) and tumor angiogenesis
por: Bid, Hemant Kumar, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_83rcpcq88rsobseh4u5a79sbp3